India: Court Orders Continuance Of Stem Cell Treatment In The Interim Till New Regulatory Approvals Are Procured

Regulatory uncertainty concerning stem cell treatment in India has been a polarizing issue. In a recent Delhi High Court judgement (Mr. Raghubir Singh and Another v. Union of India and Another dated May 28, 2019), the court passed a ruling allowing a clinic in New Delhi to continue embryonic stem cell therapy for some of their patients even in the absence of an approval under the New Drugs and Clinical Rules, 2019.

In the instant case, two patients undergoing the embryonic stem cell therapy were suffering from cerebral palsy. The clinic in question was treating these patients since October, 2018; since the notification of the New Drugs and Clinical Rules, 2019, the clinic discontinued its treatment. The medicine provided to the patients under such treatment fell within the ambit of 'new drugs' as defined in Rule 2(1)(w)(v) of the New Drugs and Clinical Rules, 2019[1] being a stem cell derived product. As per the New Drugs and Clinical Rules, 2019 in order to manufacture new drugs for the purpose of sale, permission from the Central Licencing Authority is required. After obtaining permission under the New Drugs and Clinical Rules, 2019, the person intending to manufacture a new drug for sale shall make an application for grant of licence in accordance with the provisions of the Drugs and Cosmetics Act, 1940 and its related rules. The petitioners, being the patients, pleaded that the treatment provided to them was necessary for their day to day sustenance of life and basic activities. If the treatment was discontinued, it would lead to a serious impact on their health. It was emphasised that in the time period which would lapse till the clinic obtained the marketing license, serious prejudice would be caused to the health of the petitioners. The petitioners sought directions from the court to allow the clinic to provide the treatment to the petitioners till such time the clinic obtained the necessary licences.

The court passed a judgement in favour of the petitioners allowing the treatment to be continued, provided the concerned clinic submits all the information related to the treatment being afforded to the petitioners to the Central Drugs Standard Control Organisation within a period of one week from the date of the order. As an interim measure and till such time as the said clinic or at least some other clinic applied for a licence and the licence was processed, the concerned clinic was allowed to provide treatment to the petitioners.

The National Guidelines for Stem Cell Research 2017 ("2017 Guidelines") drafted by the Indian Council of Medical Research ("ICMR"), provide that any stem cell use in patients, other than for hematopoietic stem cell (cells usually found in bone marrow, peripheral blood or umbilical cord blood) reconstitution for approved indications, is investigational. Accordingly, any stem cell use in patients must only be done within the purview of an approved and monitored clinical trial with the intent to advance science and medicine, and not offer the same as therapy. In accordance with this stringent definition, every use of stem cells in patients outside an approved clinical trial would be unethical and be considered as malpractice.

The directory nature of these guidelines, lack of enforcement or presence of any other specific law on the subject has led to the mushrooming of many clinics that provide stem cell treatments without putting the stem cell related products through clinical trials.

The Ministry of Health and Family Welfare on April 04, 2018 had proposed a draft to amend the Drug and Cosmetics Rules, 1945 which included stem cells in the definition of 'new drugs' however it excluded 'minimally manipulated stem cells' from the definition of a 'drug' and exempted it from the purview of the Drugs and Cosmetics Rules, 1945. This drew the ire of the ICMR that viewed the proposed amendment as a contradiction to the 2017 Guidelines as the exclusion of 'minimally manipulated' stem cells, would be exploited as a loophole and allow doctors to offer unproven and unregulated stem cell therapies.

Before the proposed amendment came into force, the New Drugs and Clinical Rules, 2019 were notified which included 'stem cell derived products' without creating any exemptions for 'minimally manipulated stem cells'. The New Drugs and Clinical Rules, 2019, in fact, do not define stem cell derived products at all. Accordingly, several clinics that have been providing stem cell based treatments would have to discontinue such therapies as they are now required to obtain relevant licences to continue their operations.

The judgement in this instance, even though, an apparent boon for the petitioners concerned, allows a clinic to provide treatment which hasn't been approved through trials or received a licence. The court has chosen a humanitarian course by permitting such treatment to continue however, only till the time the concerned clinic or any other clinic obtains the necessary licence. Further, the language of the judgement makes it clear that such a treatment can only be administered to the petitioners (who are parties to the writ petition) and not to any other existing or new patients who require stem cell therapy. It nevertheless lays down a precedent for other clinics and their patients to follow suit and plead for such favourable orders. In the bargain to protect patient health, courts must duly consider the intent of regulatory teeth being given by way of the New Drugs and Clinical Rules, 2019 to monitor the stem cell therapy process, lest it becomes a get-out-of-trial card for profiteering clinics.

[1] Under Section 2(1)(w) "new drug" means- (i) a drug, including active pharmaceutical ingredient or phytopharmaceutical drug, which has not been used in the country to any significant extent, except in accordance with the provisions of the Act and the rules made thereunder, as per conditions specified in the labelling thereof and has not been approved as safe and efficacious by the Central Licencing Authority with respect to its claims; or (ii) a drug approved by the Central Licencing Authority for certain claims and proposed to be marketed with modified or new claims including indication, route of administration, dosage and dosage form; or (iii) a fixed dose combination of two or more drugs, approved separately for certain claims and proposed to be combined for the first time in a fixed ratio, or where the ratio of ingredients in an approved combination is proposed to be changed with certain claims including indication, route of administration, dosage and dosage form; or (iv) a modified or sustained release form of a drug or novel drug delivery system of any drug approved by the Central Licencing Authority; or (v) a vaccine, recombinant Deoxyribonucleic Acid (r-DNA) derived product, living modified organism, monoclonal anti-body, stem cell derived product, gene therapeutic product or xenografts, intended to be used as drug.

© 2018, Vaish Associates Advocates,
All rights reserved
Advocates, 1st & 11th Floors, Mohan Dev Building 13, Tolstoy Marg New Delhi-110001 (India).

The content of this article is intended to provide a general guide to the subject matter. Specialist professional advice should be sought about your specific circumstances. The views expressed in this article are solely of the authors of this article.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions